Anti-VEGF (vascular endothelial growth factor) therapies dramatically halt the progression of CNV in most wet-AMD patients, but there is no effective treatment for AMD patients with geographic atrophy. The gene discussed is VEGFA; the disease is atrophic macular degeneration.